Abstract:Methotrexate (MTX) has been a longstanding therapeutic option for mycosis fungoides (MF); however, data on its real‐world effectiveness remain limited. This study aimed to assess real‐world outcomes of oral MTX in the treatment of MF. Data from five referral centres for cutaneous lymphoma in Greece were retrospectively reviewed with the baseline‐ and treatment‐related characteristics of patients extracted and analysed accordingly. In total, 211 patients were included in the study. MTX demonstrated greater effectiveness as a first‐line treatment compared to subsequent use with no significant differences between monotherapy and combination therapy. No significant differences were observed between MTX monotherapy and MTX combined with other treatments. Patients with early‐stage disease (IA‐IIA) achieved favourable outcomes along with patients with erythrodermic disease (Stage III). Patients with Stage IV and IIB disease had the worst responses. The presence of the folliculotropic variant of MF did not affect responses to treatment while large cell transformation had a negative impact on responses. Overall, MTX demonstrated acceptable safety and a small amount of patients discontinued the medication due to adverse events. The findings of this large multicentric study support MTX as a viable treatment option for MF, particularly when used in the first line setting, offering a favourable benefit/risk profile. Response rates are stage‐dependent, with erythrodermic patients achieving superior and durable responses. Background Methotrexate (MTX) has been a longstanding therapeutic option for mycosis fungoides (MF); however, data on its real‐world effectiveness remain limited. Objectives To evaluate treatment‐related outcomes of oral MTX in patients with early‐ and late‐stage MF. Methods This is a retrospective multicentre analysis involving MF subjects from five referral centres for cutaneous lymphomas in Greece. Data regarding the effectiveness and safety were analysed. Results In total, 211 MF patients were enrolled (males, 68.3%) with a median (IQR) age of diagnosis at 68.3 (56–75) years. Late‐stage (IIB‐IVB) disease was present in 124 patients (59.3%). MTX monotherapy was administered to 112 (53.1%) patients, with 99 receiving combination regimens with phototherapy, interferon and retinoids. MTX was used as first‐line regimen in 103 (48.9%) cases. An overall response rate (ORR) of 55.5% was observed with 29.9% of patients achieving complete responses. MTX demonstrated greater effectiveness as a first‐line treatment compared to subsequent use with no significant differences between monotherapy and combination therapy. The median time to best response was 3.8 months (IQR 2.3–9.9 months). Patients with erythrodermic disease (Stage III) had better ORRs compared to patients with tumour stage disease (Stage II) (61.1% vs. 44.8% respectively). The progression‐free survival (PFS) varied according to stage, with a median PFS of 17.1 months for early‐stage disease, 5.7 months for Stage IIB disease, 46 months for Stage III and 9.6 months for Stage IV disease (0.7‐.). Serious adverse (Grade 3) events leading to treatment discontinuation occurred in 14 (6.7%) cases. All patients received oral MTX once weekly with a median weekly dose of 15 mg/week (7.5–25). Conclusion Our findings support MTX as a viable treatment option for MF, particularly when used in the first‐line setting, offering a favourable benefit/risk profile. Response rates are stage‐dependent, with erythrodermic patients achieving superior and durable responses.

Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis

Usefulness of Tocilizumab for Treating Rheumatoid Arthritis with Myelodysplastic Syndrome

The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting

Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study

AB0100 Mtx combined with ctx inhibited il-6 induced jak2-stat3 activation and the induction of p-gp in peripheral blood lymphocytes of rheumatoid arthritis patients

CASE SERIES ON METHOTREXATE INDUCED BONE MARROW SUPPRESSION

Methotrexate: new therapeutic approaches

Methotrexate Toxicity-Induced Pancytopenia and Mucocutaneous Ulcerations in Psoriasis

[Therapeutic Effect and Impact on Cytokine Production by Methotrexate in Rheumatoid Arthritis].

Efficacy and Safety of Methotrexate in Psoriasis Vulgaris Long-Term Treatment: A Real-World Observation Study

A Rare Case of Acute Methotrexate Toxicity Leading to Bone Marrow Suppression

Methotrexate and cardiovascular prevention: an appraisal of the current evidence

A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate

[Low-dose methotrexate: Indications and side effects, particularly in cases of diffuse interstitial pneumonia]

Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis

Delayed low-dose methotrexate excretion in a rheumatoid arthritis patient: A case report and literature review

Single-cell RNA transcriptomic and plasma Lipidomic reveal the potential mechanisms of a Methotrexate-based therapy against Rheumatoid Arthritis

Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation

Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic

Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis

Methotrexate might become the sole treatment option for leukemia following the occurrence of Stevens-Johnson syndrome